PNPLA3 and metabolic dysfunction-associated steatotic liver disease: In addition, according to literature evidence [30,31], HCC patients display an increased frequency distribution of PNPLA3 variant (29% MM vs. 16%; p < 0.0001 at one-way ANOVA) compared to NAFLD patients without cancer.